Abstract
Renal involvement occurs in 50-75% of children with childhood-onset systemic lupus erythematosus (cSLE). Proliferative lupus nephritis (LN) represents the most common pattern of renal involvement in cSLE. Despite aggressive treatment, progression to end stage renal disease can occur in up to 5-10% of children. Over the last 2 decades, tremendous advancements have been made in the treatment of pediatric LN. Special considerations in children need to address the impact of disease and therapy on both physical and psychological growth and development. This review will focus on pivotal clinical trials in the treatment of proliferative LN, with a focus on pediatric data when available.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference71 articles.
1. The classification of glomerulonephritis in systemic lupus erythematosus revisited.;J Weening;J Am Soc Nephrol.,2004
2. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions.;N Hiramatsu;Rheumatology (Oxford).,2008
3. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.;M Faurschou;J Rheumatol.,2006
4. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy.;N Baqi;J Am Soc Nephrol.,1996
5. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults.;K Gibson;Clin J Am Soc Nephrol.,2009